Transient retinal arterial occlusion

Summary

Transient retinal arterial occlusion (MONDO:0004583) is a disease. A subtype of retinal artery occlusion — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	transient retinal arterial occlusion
Mondo ID	MONDO:0004583
DOID	DOID:8482
NCIT	C35193
SNOMED CT	87224000
UMLS	C0154840
MedGen	102320
Is cancer (heuristic)	no

Also known as: transient retinal arterial occlusion

Disease family

This is a subtype of retinal artery occlusion. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › retinal disorder › retinal vascular disorder › retinal vascular occlusion › retinal artery occlusion › transient retinal arterial occlusion

Related subtypes (3): branch retinal artery occlusion, central retinal artery occlusion, partial arterial retinal occlusion

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.